Literature DB >> 17698090

Management of low grade papillary bladder tumors.

Harry W Herr1, S Machele Donat, Victor E Reuter.   

Abstract

PURPOSE: We evaluated the management and treatment outcomes of low grade papillary bladder tumors.
MATERIALS AND METHODS: We evaluated 215 patients diagnosed with low grade and noninvasive papillary bladder tumors, and followed them every 6 months with flexible cystoscopy for 6 to 10 or more years. Tumor recurrence was treated with transurethral resection or outpatient cystoscopic fulguration.
RESULTS: Of the 215 patients 143 (67%) had at least 1 recurrence (positive cystoscopy). With a median followup of 8 years tumor recurrences averaged 6.2 (range 1 to 19) requiring 0.34 transurethral resections per year or 1 transurethral resection every 3 years, or 0.61 fulgurations or 1 fulguration approximately every 2 years. There were 17 patients (8%) who had progression in grade or stage and 1 patient (0.5%) died of bladder cancer. Patients most likely to have recurrence had multiple tumors, low grade (TaLG) carcinoma or tumor at first followup cystoscopy.
CONCLUSIONS: Surveillance cystoscopy at 6-month intervals coupled with outpatient fulguration controls recurrent tumors and reduces the therapeutic burden for patients diagnosed with low grade papillary bladder tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17698090     DOI: 10.1016/j.juro.2007.05.148

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.

Authors:  Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

2.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

Authors:  Isaac Kinde; Enrico Munari; Sheila F Faraj; Ralph H Hruban; Mark Schoenberg; Trinity Bivalacqua; Mohamad Allaf; Simeon Springer; Yuxuan Wang; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; George J Netto
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.

Authors:  Chinedu O Mmeje; Charles C Guo; Jay B Shah; Neema Navai; H Barton Grossman; Colin P Dinney; Ashish M Kamat
Journal:  Eur Urol       Date:  2016-02-24       Impact factor: 20.096

4.  [Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Authors:  F Vom Dorp; S Tschirdewahn; T Szarvas; H Rübben; R Kraemer; C Rehme
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

5.  Urothelial neoplasms in pediatric and young adult patients: A large single-center series.

Authors:  James A Saltsman; Marcus M Malek; Victor E Reuter; William J Hammond; Enrico Danzer; Harry W Herr; Michael P LaQuaglia
Journal:  J Pediatr Surg       Date:  2017-11-14       Impact factor: 2.545

Review 6.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

7.  Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.

Authors:  Sheila F Faraj; Enrico Munari; Gunes Guner; Janis Taube; Robert Anders; Jessica Hicks; Alan Meeker; Mark Schoenberg; Trinity Bivalacqua; Charles Drake; George J Netto
Journal:  Urology       Date:  2015-03       Impact factor: 2.649

Review 8.  Guideline of guidelines: non-muscle-invasive bladder cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia; Yair Lotan
Journal:  BJU Int       Date:  2017-01-24       Impact factor: 5.588

9.  Tumour Behaviour of Low-Grade Papillary Urothelial Carcinoma: A Single-Centre Retrospective Study.

Authors:  Satya Dutta; Biswajit Dey; Vandana Raphael; Yookarin Khonglah; Jaya Mishra; Evarisalin Marbaniang; Pranjal Kalita; Stephen Sailo
Journal:  Cureus       Date:  2021-06-29

10.  Clinical Use Cases for a Tool to Assess Risk in Superficial Bladder Cancer.

Authors:  Carmit K McMullen; Maureen O'Keeffe Rosetti; Sheila Weinmann; Michael C Leo; Matthew E Nielsen
Journal:  Perm J       Date:  2019-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.